C-peptide: difference between revisions
Diff·revision 10 → 11·17:41, 17 Jan 2025
Difference between revision 10 and revision 11 of C-peptide. 16 lines changed; the page grew by 677 bytes.
| Revision 10 — 01:37, 23 Dec 2024 AxisLabelAgda (talk) add the note that the marker changes with weight loss independently of the drug 2,573 bytes +36 | Revision 11 — 17:41, 17 Jan 2025 DrTitration (talk) clarify that the marker is method-dependent and not comparable across platforms 3,250 bytes +677 | ||
|---|---|---|---|
| 21 | The most common clinical use is classification: a very low C-peptide with hyperglycaemia indicates insulin deficiency, while a normal or high value with hyperglycaemia indicates resistance with preserved secretion. The thresholds are assay- and context-dependent.{{r|jones2013}} | 21 | The most common clinical use is classification: a very low C-peptide with hyperglycaemia indicates insulin deficiency, while a normal or high value with hyperglycaemia indicates resistance with preserved secretion. The thresholds are assay- and context-dependent.{{r|jones2013}} |
| 22 | 22 | ||
| + | 23 | == Interpretation caveats == | |
| + | 24 | | Situation | Effect on C-peptide | | |
| + | 25 | |---|---| | |
| + | 26 | | Renal impairment | Raised, independent of secretion | | |
| + | 27 | | Fasting versus stimulated | Different questions; not interchangeable | | |
| + | 28 | | Exogenous insulin | Suppresses endogenous secretion, lowering C-peptide | | |
| + | 29 | | Assay differences | Between-method variation is substantial | | |
| + | 30 | ||
| + | 31 | The exogenous insulin row is the basis of one of the analyte's forensic uses: insulin administered from outside raises insulin while suppressing C-peptide, a pattern that endogenous hypersecretion does not produce.{{r|jones2013}} | |
| + | 32 | ||
| 23 | == References == | 33 | == References == |
| 24 | {{reflist}} | 34 | {{reflist}} |
| ⋮ | ⋮ | ||
| 26 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 36 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| 27 | <ref name="rorsman2013">Rorsman P, Braun M. "Regulation of insulin secretion in human pancreatic islets." ''Annual Review of Physiology'' 75:155–179 (2013). PMID 22974438.</ref> | 37 | <ref name="rorsman2013">Rorsman P, Braun M. "Regulation of insulin secretion in human pancreatic islets." ''Annual Review of Physiology'' 75:155–179 (2013). PMID 22974438.</ref> |
| + | 38 | ||
| + | 39 | == See also == | |
| + | 40 | * [[Insulin secretion]] | |
| + | 41 | * [[Beta cell function]] | |
| + | 42 | * [[Fasting insulin]] | |
| + | 43 | * [[HOMA-IR]] | |
| 28 | 44 | ||
| 29 | {{DEFAULTSORT:C-peptide}} | 45 | {{DEFAULTSORT:C-peptide}} |